EGFR and cancer: Remarkably, we found enrichment of several cancer-specific pathways, including breast, colorectal, gastric, pancreatic, prostate, and lung cancers (Fig. 4D), in addition to more general cancer-related pathways, such as P53, ErbB, and MAPK signaling, as well as resistance to platinum drugs and EGFR tyrosine kinase inhibitors (Supplementary Table S9).